公开(公告)号：US20100003245A1

公开(公告)日：2010-01-07

申请号：US12374473

申请日：2007-07-19

申请人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

发明人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

IPC分类号： A61K39/395 ,  C12N5/06 ,  C07K16/18

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/76

摘要： When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

摘要翻译： 当将抗人BMP抗体加入到在人BMP存在下培养的永生化人肾小球系膜细胞的细胞中时，抗人BMP抗体显着抑制肾小球系膜细胞中IV型胶原的产生。 许多信号通路涉及IV型胶原异常增殖。 因此，完全不可预测的是，只是阻断BMP信号将确实抑制IV型胶原蛋白的异常增殖。 然而，本发明人第一次证明抗BMP抗体在抑制IV型胶原蛋白的异常增殖方面非常有效。 因此，抗BMP抗体可用作与肾小球系膜基质异常增殖相关的肾脏疾病的新型治疗剂。

公开(公告)号：US20100135988A1

公开(公告)日：2010-06-03

申请号：US12585882

申请日：2009-09-28

申请人： Toshio Doi ,  Hideharu Abe

发明人： Toshio Doi ,  Hideharu Abe

IPC分类号： A61K39/395 ,  C12Q1/00 ,  C12Q1/68 ,  G01N33/53 ,  C12Q1/48 ,  G01N33/561 ,  A61K31/7088

CPC分类号： C12Q1/6883 ,  A61K45/06 ,  C07K16/2863 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/51 ,  G01N2333/71

摘要： A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

摘要翻译： 一种检测引起硬化的增殖性疾病的方法，包括测量选自STAT3，磷酸化STAT3，Smad1，磷酸化Smad1，激活素受体样激酶1，激活素受体样激酶3和骨形态发生的至少一种物质的表达 生物样品中的蛋白质。 一个套件。 一种引起硬化的增殖性疾病的预防和/或治疗剂，其包含作为活性成分的对STAT3，磷酸化STAT3，Smad1和磷酸化Smad1中选择的至少一种物质的表达具有抑制作用的物质。 鉴定有效预防和/或治疗引起硬化的增殖性疾病的物质的方法，包括判断测试物质是否抑制至少一种选自STAT3，磷酸化STAT3，Smad1和磷酸化Smad1的物质的表达。 一个套件。

公开(公告)号：US08025881B2

公开(公告)日：2011-09-27

申请号：US12374473

申请日：2007-07-19

申请人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

发明人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

IPC分类号： A61K39/395 ,  C12N5/12 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/76

摘要： When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

摘要翻译： 当将抗人BMP抗体加入到在人BMP存在下培养的永生化人肾小球系膜细胞的细胞中时，抗人BMP抗体显着抑制肾小球系膜细胞中IV型胶原的产生。 许多信号通路涉及IV型胶原异常增殖。 因此，完全不可预测的是，只是阻断BMP信号将确实抑制IV型胶原蛋白的异常增殖。 然而，本发明人第一次证明抗BMP抗体在抑制IV型胶原蛋白的异常增殖方面非常有效。 因此，抗BMP抗体可用作与肾小球系膜基质异常增殖相关的肾脏疾病的新型治疗剂。

公开(公告)号：US07862993B2

公开(公告)日：2011-01-04

申请号：US10571511

申请日：2004-09-09

申请人： Toshio Doi ,  Hideharu Abe

发明人： Toshio Doi ,  Hideharu Abe

IPC分类号： G01N33/48 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68

摘要： A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

公开(公告)号：US09359645B2

公开(公告)日：2016-06-07

申请号：US12585882

申请日：2009-09-28

申请人： Toshio Doi ,  Hideharu Abe

发明人： Toshio Doi ,  Hideharu Abe

IPC分类号： A61K31/00 ,  A61K38/00 ,  A61K39/395 ,  G01N33/53 ,  C12Q1/68 ,  A61K45/06

CPC分类号： C12Q1/6883 ,  A61K45/06 ,  C07K16/2863 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/51 ,  G01N2333/71

摘要： A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

摘要翻译： 一种检测引起硬化的增殖性疾病的方法，包括测量选自STAT3，磷酸化STAT3，Smad1，磷酸化Smad1，激活素受体样激酶1，激活素受体样激酶3和骨形态发生的至少一种物质的表达 生物样品中的蛋白质。 一个套件。 一种引起硬化的增殖性疾病的预防和/或治疗剂，其包含作为活性成分的对STAT3，磷酸化STAT3，Smad1和磷酸化Smad1中选择的至少一种物质的表达具有抑制作用的物质。 鉴定有效预防和/或治疗引起硬化的增殖性疾病的物质的方法，包括判断测试物质是否抑制至少一种选自STAT3，磷酸化STAT3，Smad1和磷酸化Smad1的物质的表达。 一个套件。

公开(公告)号：US07901874B2

公开(公告)日：2011-03-08

申请号：US10571511

申请日：2004-09-09

申请人： Toshio Doi ,  Hideharu Abe

发明人： Toshio Doi ,  Hideharu Abe

IPC分类号： G01N33/48 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68

CPC分类号： C12Q1/6883 ,  A61K45/06 ,  C07K16/2863 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/51 ,  G01N2333/71

摘要： A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

摘要翻译： 一种检测引起硬化的增殖性疾病的方法，包括测量选自STAT3，磷酸化STAT3，Smad1，磷酸化Smad1，激活素受体样激酶1，激活素受体样激酶3和骨形态发生的至少一种物质的表达 生物样品中的蛋白质。 一个套件。 一种引起硬化的增殖性疾病的预防和/或治疗剂，其包含作为活性成分的对STAT3，磷酸化STAT3，Smad1和磷酸化Smad1中选择的至少一种物质的表达具有抑制作用的物质。 鉴定有效预防和/或治疗引起硬化的增殖性疾病的物质的方法，包括判断测试物质是否抑制至少一种选自STAT3，磷酸化STAT3，Smad1和磷酸化Smad1的物质的表达。 一个套件。

公开(公告)号：US20080025967A1

公开(公告)日：2008-01-31

申请号：US10571511

申请日：2004-09-09

申请人： Toshio Doi ,  Hideharu Abe

发明人： Toshio Doi ,  Hideharu Abe

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61P43/00 ,  C12Q1/48 ,  G01N33/53

CPC分类号： C12Q1/6883 ,  A61K45/06 ,  C07K16/2863 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/51 ,  G01N2333/71

摘要： A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

摘要翻译： 一种检测引起硬化的增殖性疾病的方法，包括测量选自STAT3，磷酸化STAT3，Smad1，磷酸化Smad1，激活素受体样激酶1，激活素受体样激酶3和骨形态发生的至少一种物质的表达 生物样品中的蛋白质。 一个套件。 一种引起硬化的增殖性疾病的预防和/或治疗剂，其包含作为活性成分的对STAT3，磷酸化STAT3，Smad1和磷酸化Smad1中选择的至少一种物质的表达具有抑制作用的物质。 鉴定有效预防和/或治疗引起硬化的增殖性疾病的物质的方法，包括判断测试物质是否抑制至少一种选自STAT3，磷酸化STAT3，Smad1和磷酸化Smad1的物质的表达。 一个套件。